Novartis Reports PARADIGM-HF Results for Entresto in Heart Failure

Novartis today announced results from the Phase 3 PARADIGM-HF trial evaluating Entresto (sacubitril/valsartan) versus enalapril in patients with heart failure with reduced ejection fraction. The trial met its primary endpoint, demonstrating a significant reduction in cardiovascular mortality and heart failure hospitalization with Entresto. The risk of cardiovascular death was reduced by 20%.